Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

Bruton tyrosine kinase (BTK) is expressed in B cells and innate immune cells, acting as an essential signaling element in multiple immune cell pathways. Selective BTK inhibition has the potential to target multiple immune-mediated disease pathways. Rilzabrutinib is an oral, reversible, covalent BTK...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunol
Hlavní autoři: Langrish, Claire L., Bradshaw, J. Michael, Francesco, Michelle R., Owens, Timothy D., Xing, Yan, Shu, Jin, LaStant, Jacob, Bisconte, Angelina, Outerbridge, Catherine, White, Stephen D., Hill, Ronald J., Brameld, Ken A., Goldstein, David M., Nunn, Philip A.
Médium: Artigo
Jazyk:Inglês
Vydáno: AAI 2021
Témata:
Autoimmunity
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7980532/
https://ncbi.nlm.nih.gov/pubmed/33674445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.2001130
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky